Crossmark

Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER)

Crossref DOI link: https://doi.org/10.1136/bmjdrc-2022-002785

Published Online: 2022-06-09

Published Print: 2022-06

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Kharitonova, Tatiana https://orcid.org/0000-0003-4021-9421
Shvarts, Yury G

Verbovoy, Andrey F

Orlova, Natalia S

Puzyreva, Valentina P

Strokov, Igor A
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04649203 at ClinicalTrials.gov

Documents that mention this clinical trial

Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER)
https://doi.org/10.1136/bmjdrc-2022-002785
Funding

Funding for this research was provided by:

POLYSAN Scientific & Technological Pharmaceutical Company
License Information

License valid from 2022-06-08

Document is current

Any future updates will be listed below